# Using Biomarkers to Predict TB Treatment Duration

> **NCT02821832** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 946 (actual)

## Conditions studied

- Pulmonary Tuberculosis

## Interventions

- **PROCEDURE:** Saliva collection
- **PROCEDURE:** Urine collection
- **PROCEDURE:** Sputum collection
- **PROCEDURE:** Blood Collection
- **RADIATION:** PET/CT Scan
- **DRUG:** Isoniazid, Rifampicin, Pyrazinamide and Ethambutol

## Key facts

- **NCT ID:** NCT02821832
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-21
- **Primary completion:** 2021-10-09
- **Final completion:** 2022-02-28
- **Target enrollment:** 946 (ACTUAL)
- **Last updated:** 2024-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02821832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02821832, "Using Biomarkers to Predict TB Treatment Duration". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02821832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*